How are medical comorbidities managed in patients with myelodysplastic syndrome (MDS)?

Updated: Jul 24, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print
Answer

Patients with associated serious medical comorbidities should be treated with less aggressive agents such as azacitidine or arsenic trioxide (Trisenox), or they should be entered into a clinical trial. However, these are currently in the early experimental stages.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!